Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ENOV
Enovis Corporation
Enovis Corporation (ENOV) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.7
/ 5.0
C+
Value
B
Factor Score
3.3
/ 5.0
Growth
C-
Factor Score
1.9
/ 5.0
Profitability
B-
Factor Score
3.0
/ 5.0
Momentum
C+
Factor Score
2.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
8.0
EV / EBITDA
7.7
Rev Growth YoY
1.8%
Gross Margin
61.3%
Price Return 3M
14.3%
Price Return 12M
0.6%
Catalyst Signal
0.00
Market Cap
$1.6B
TTM Revenue
$2.3B
Price / Sales
0.7
ROE
-30.0%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B (3.3) | C- (1.9) | B- (3.0) | C+ (2.5) | C+ (2.6) | C+ (2.7) |
| 2026-11-04 | B (3.3) | C- (1.9) | B- (3.0) | D+ (1.7) | C+ (2.7) | C+ (2.5) |
| 2026-10-28 | B (3.3) | C- (1.9) | B- (2.9) | D+ (1.6) | C+ (2.7) | C (2.5) |
| 2026-10-21 | B (3.3) | C- (1.9) | B- (2.9) | D+ (1.7) | C+ (2.6) | C (2.5) |
| 2026-10-14 | B (3.3) | C- (1.9) | B- (2.9) | D+ (1.7) | C+ (2.6) | C (2.5) |
Page
1
of
4